Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.
|Articles|April 5, 2023
Pharma USA 2023: IRA Impact on Patients
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on Medicare patients' affordability.
Advertisement
Related to this article
Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015.
Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
5